This Certificate of Analysis covers batch LZ-SHB-261001 of Super Human Blend, manufactured on October 1, 2026 and analysed on October 17, 2026. Purity is 99.06% by RP-HPLC, against a specification of ≥99.0%. Identity was confirmed by mass spectrometry at 162.21, within the expected [M+H]⁺ = 162.21 ± 0.5. The batch was released on October 20, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.
2–8°C (refrigerated), protected from light, up to 4 weeks
Long-term
2–8°C (refrigerated), protected from light, 24 months; do not freeze
After opening
Use within 28 days; store at 2–8°C
Handling
Protect from light and moisture; use aseptic technique
Reconstitution
Pre-formulated sterile solution, no reconstitution required
Sample identification and chain of custody
Sample identifier
SMP-261001-239
Received on
October 1, 2026
Received from
Production, as the released source batch following synthesis and compounding, prior to filling
Presented as
2 sealed samples drawn from the homogenised source batch
Condition on receipt
Seals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt
2 to 8 °C, protected from light
Tested between
October 1, 2026 to October 17, 2026
Retained sample
One sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12
Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.
HPLC chromatogram
Reversed-phase trace for this batch. Peak assignments and integration are in the table below.
Chromatographic method and system suitability
Technique
Reversed-phase ion-pair HPLC
Column
C18, 250 x 4.6 mm, 5 µm, 100 Å
Column temperature
30 °C
Mobile phase A
10 mM sodium hexanesulfonate with 0.1% phosphoric acid in water
Mobile phase B
Acetonitrile
Gradient
5% to 80% B over 25 min, re-equilibrate 5 min
Flow rate
1.0 mL/min
Detection
UV 210 nm (diode array 190 to 400 nm)
Injection
10 µL
Run time
35 min
Diluent
Mobile phase A / acetonitrile (90:10)
System suitability
Requirement
Result
Tailing factor, main peak
≤ 2.0
1.04
Theoretical plates, main peak
≥ 2,000
12,804
Resolution, closest eluting pair
≥ 2.0
4.6
Injection repeatability, %RSD (n = 6)
≤ 2.0%
0.43%
Reference standard recovery
98.0 to 102.0%
100.1%
Peak integration
Peak
RT (min)
RRT
Area
Area %
Assignment
1
3.08
0.82
9,345
0.34
Related substance
2
3.42
0.91
6,597
0.24
Related substance
3
3.80
1.00
2,722,758
99.06
Limiting component
4
4.03
1.07
5,222
0.19
Related substance
5
4.49
1.19
4,673
0.17
Related substance
Total area 2,748,595. Total area accounted for 100.00%. Area normalisation for the limiting component shown. Each component is assayed against its own reference standard in the results table; peaks below 0.05% of total area are excluded.
Orthogonal identity confirmation
Test
Method
Requirement
Result
Component identity by co-elution
RP-HPLC co-injection against each component reference standard
Each component co-elutes with its reference standard; no unassigned peak above 0.5%
Every declared component co-eluted with its reference standard
A blend's headline purity says nothing about which components are present, so each one is confirmed against its own reference standard.
Component assay and blend ratio
Intended shares are calculated from the composition declared on the product page, so the certificate and the product cannot state different formulations. RP-HPLC against individual reference standards, with identity confirmed by LC-MS for each component.
Component
Declared
Intended
Measured
Acceptance
Purity
Identity
L-Arginine
110 mg
12.7% w/w
12.8% w/w
12.1 to 13.4% w/w
99.63%
[M+H]⁺ = 175.21 ± 0.3, observed 175.21
L-Ornithine
110 mg
12.7% w/w
12.8% w/w
12.1 to 13.4% w/w
99.48%
[M+H]⁺ = 133.16 ± 0.3, observed 133.16
L-Citrulline
120 mg
13.9% w/w
14.1% w/w
13.2 to 14.6% w/w
99.24%
[M+H]⁺ = 176.20 ± 0.3, observed 176.20
L-Lysine
70 mg
8.1% w/w
8.2% w/w
7.7 to 8.5% w/w
99.68%
[M+H]⁺ = 147.20 ± 0.3, observed 147.20
L-Glutamine
40 mg
4.6% w/w
4.7% w/w
4.4 to 4.9% w/w
99.06%
[M+H]⁺ = 147.15 ± 0.3, observed 147.15
L-Proline
60 mg
6.9% w/w
7.0% w/w
6.6 to 7.3% w/w
99.79%
[M+H]⁺ = 116.14 ± 0.3, observed 116.14
L-Taurine
60 mg
6.9% w/w
6.8% w/w
6.6 to 7.3% w/w
99.62%
[M+H]⁺ = 126.15 ± 0.3, observed 126.15
L-Carnitine
220 mg
25.4% w/w
25.9% w/w
24.2 to 26.7% w/w
99.81%
[M+H]⁺ = 162.21 ± 0.3, observed 162.21
NAC (N-Acetyl Cysteine)
75 mg
8.7% w/w
8.7% w/w
8.2 to 9.1% w/w
99.42%
[M+H]⁺ = 164.20 ± 0.3, observed 164.20
The headline purity on this certificate is the lowest single-component purity. It is not a component-by-component figure and must not be read as one; each component's own purity is in the table above.
Batch-to-batch consistency
Lot
Certificate
Manufactured
Analysed
Purity
Water
Endotoxin
Disposition
LZ-SHB-261001 (this lot)
LZ-COA-SHB-261005
October 1, 2026
October 17, 2026
99.06%
6.20%
<0.1 EU/mg
Released
LZ-SHB-260916
LZ-COA-SHB-260920
September 16, 2026
September 18, 2026
99.30%
5.98%
<0.1 EU/mg
Released, superseded October 15, 2026
LZ-SHB-260911
LZ-COA-SHB-260915
September 11, 2026
September 13, 2026
99.11%
5.57%
<0.1 EU/mg
Released, superseded September 16, 2026
Purity range 99.06% to 99.30%, 0.24 percentage points across 3 lots, against ≥99.0%. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.
Residual solvents
Solvent
Class
Limit
Result
LOQ
Acetonitrile
Class 2
410 ppm
125 ppm
10 ppm
Dichloromethane
Class 2
600 ppm
95 ppm
10 ppm
N,N-Dimethylformamide
Class 2
880 ppm
< 10 ppm
10 ppm
Methanol
Class 2
3,000 ppm
361 ppm
50 ppm
Diethyl ether
Class 3
5,000 ppm
294 ppm
50 ppm
Piperidine
In-house
100 ppm
20 ppm
5 ppm
Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.
Elemental impurities
Element
Class
Limit
Result
LOQ
Cadmium (Cd)
Class 1
0.20 ppm
< 0.05 ppm
0.05 ppm
Lead (Pb)
Class 1
0.50 ppm
< 0.05 ppm
0.05 ppm
Arsenic (As)
Class 1
1.50 ppm
< 0.10 ppm
0.10 ppm
Mercury (Hg)
Class 1
0.30 ppm
< 0.05 ppm
0.05 ppm
Cobalt (Co)
Class 2A
0.50 ppm
< 0.05 ppm
0.05 ppm
Nickel (Ni)
Class 2A
2.00 ppm
0.60 ppm
0.10 ppm
Vanadium (V)
Class 2A
1.00 ppm
< 0.10 ppm
0.10 ppm
Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.
Microbiological testing
Test
Method
Limit
Result
Total aerobic microbial count (TAMC)
USP <61>, membrane filtration
≤ 100 CFU/mL
< 10 CFU/mL
Total combined yeasts and moulds (TYMC)
USP <61>, membrane filtration
≤ 10 CFU/mL
< 10 CFU/mL
Escherichia coli
USP <62>
Absent in 1 mL
Absent
Staphylococcus aureus
USP <62>
Absent in 1 mL
Absent
Pseudomonas aeruginosa
USP <62>
Absent in 1 mL
Absent
Salmonella species
USP <62>
Absent in 10 mL
Absent
Bile-tolerant Gram-negative bacteria
USP <62>
≤ 10 CFU/mL
< 10 CFU/mL
Sterility
USP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °C
No growth
No growth in either medium at 14 days
Method suitability (bacteriostasis and fungistasis) confirmed on this solution matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.
Independent confirmation
Laboratory
Janoshik Analytical
Accreditation
ISO/IEC 17025:2017
Role
Independent confirmation, no commercial interest in the result
Our cross-reference
LZ-IND-261001-450
Sample reference
LZ-SHB-261001
Scope of independent testing
Chromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
Outcome
Independent result agrees with the in-house release result within the method's stated repeatability
LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.
Manufacturing and document control
Manufacturing site reference
LZ-SITE-01
Site scope
Solid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality system
Operated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared by
Quality Control Analyst
Reviewed by
Quality Control Supervisor
Approved by
Quality Assurance Director
Document revision
1
Release status
RELEASED
Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.
Analytical testing. Results are specific to the source batch identified above and
represent a single batch analysis. Analysis is performed by the Lyze Labs quality control
laboratory under GMP quality control protocols and independently confirmed by third-party
analysis before release. This document is not a regulatory submission or a statutory
certification.
Research use only. Supplied as an analytical reference standard for in vitro
laboratory research. Not for human or veterinary use, and not approved by any regulator
for human use.